查詢結果分析
相關文獻
- Prevalence and Clinical Relevance of Serum Autoantibodies in Patients with Chronic Hepatitis C
- Prevalence of Autoantibodies in Uremic Patients with HCV Infection
- 臺灣肝臟病系列(40):慢性C型肝炎之抗病毒治療
- Type 1 Autoimmune Hepatitis Mimic Cryptogenic Hepatitis
- Combination Interferon α-2b Plus Ribavirin Therapy in Patients with Chronic Hepatitis C with Resistance to or Relapse after Interferon Monotherapy
- 慢性C型肝炎患者接受抗病毒藥物治療失敗之機轉及因應措施
- (Anti-cytoplasmic Rings and Rods)抗體在C型肝炎病人治療前後之血清抗體變化
- Predictive Factors for Therapeutic Effect of Interferon Alfa-2b and Ribavirin Conbination Therapy on Chronic Hepatitis C: A Retrospective Analysis in a Mid-Taiwan Hospital
- 肝癌的流行病學
- The Effect of Age on Response to Therapy with Peginterferon Plus Ribavirin in Patients with Chronic Hepatitis C
頁籤選單縮合
題名 | Prevalence and Clinical Relevance of Serum Autoantibodies in Patients with Chronic Hepatitis C=慢性C型肝炎病人血清自體抗體之盛行率與臨床之相關性 |
---|---|
作者 | 陳志弘; 李全謨; 陳建宏; 胡琮輝; 王景弘; 洪肇宏; 鍾鏡湖; 盧勝男; | 書刊名 | 長庚醫誌 |
卷期 | 33:3 2010.05-06[民99.05-06] |
頁次 | 頁258-265 |
分類號 | 415.5332 |
關鍵詞 | C型肝炎; 抗核抗體; 抗平滑肌抗體; 持續性病毒反應; 抗病毒治療; Hepatitis C; Antinuclear antibody; Smooth muscle antibody; Sustained virological response; Antiviral therapy; |
語文 | 英文(English) |
中文摘要 | C C C 460 C ( 257 203 50.6 11.2 ) (ANA) (SMA) α-2b (376 ) -α-2b (84 ) ribavirin 1000-1200 24 ANA SMA 7.4% 19.3% ANA SMA ANA AST ANA SMA ALT C ANA SMA ANA SMA C |
英文摘要 | Background: Chronic hepatitis C (CHC) is frequently associated with the presence of serum autoantibodies. The prevalence and clinical relevance of serum autoantibodies in CHC patients and their influence on antiviral treatment have not been well established. Methods: From February 1999 to July 2004, 460 consecutive adult patients with CHC were studied. Antinuclear antibody (ANA) and smooth muscle antibody (SMA) were determined by indirect immunofluorescence. The presence of these antibodies was related to patient characteristics and to the outcome of 24 weeks of therapy with interferon (IFN) alfa-2b (n = 376) or pegylated- IFN alfa-2b (n = 84) plus ribavirin. Results: The prevalence of ANA and SMA was 7.4% and 19.3%, respectively. Seropositivity for ANA and/or SMA was associated with old age and high aspartate aminotransferase (AST) levels. The rates of sustained virological response and early withdrawal of therapy were comparable between autoantibody- positive and -negative patients. None of the autoantibody-positive patients experienced a flare-up of transaminase during treatment, or developed severe systemic autoimmune disease. Conclusion: Serum ANA and/or SMA-positive HCV-infected patients are older, and have higher disease activity and severity than their negative counterparts. However, the presence of ANA or SMA did not influence the response to combination antiviral therapy, which is safe and effective in autoantibody - positive CHC patients. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。